Hypoxia-inducible factor 2 inhibitors show promise in advanced kidney cancer

Nature Reviews Urology, Published online: 03 June 2021; doi:10.1038/s41585-021-00487-9A new phase I clinical trial has demonstrated that belzutifan provides a route to sustained inhibition of hypoxia-inducible factor 2α in humans that is well tolerated and could be useful in the treatment of advanced clear cell kidney cancer.
Source: Nature Reviews Urology - Category: Urology & Nephrology Authors: Source Type: research